二甲双胍
安普克
医学
药理学
药品
癌症
糖尿病
细胞凋亡
2型糖尿病
癌细胞
癌症研究
内科学
内分泌学
生物
蛋白激酶A
生物化学
激酶
作者
Wei Mu,Yunyun Jiang,Guoqiang Liang,Yong Feng,Fengli Qu
出处
期刊:Current Drug Targets
[Bentham Science]
日期:2023-01-01
卷期号:24 (1): 41-54
被引量:6
标识
DOI:10.2174/1389450124666221104094918
摘要
Abstract: Metformin is a widely used drug in patients with type 2 diabetes mellitus. Metformin in-hibits hepatic gluconeogenesis and increases glucose utilization in peripheral tissues. In recent years, several studies have shown that metformin is a potential therapeutic agent against cancer, alone or combined with other anticancer treatments. Metformin mainly activates the AMPK com-plex and regulates intracellular energy status, inhibiting the mitochondrial respiratory chain com-plex I and reducing the production of reactive oxygen species. Other anticancer targets of metfor-min are specific transcription factors inhibiting cell proliferation, promoting apoptosis and reducing drug resistance. In addition, metformin modulates tumor cells' response to anticancer treatments, favoring the activity of T cells. In diabetic patients, metformin reduces the occurrence of cancer and improves the prognosis and efficacy of anticancer treatments. In this review, we provided a com-prehensive perspective of metformin as an anticancer drug.
科研通智能强力驱动
Strongly Powered by AbleSci AI